{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:53:04Z","timestamp":1792090384699,"version":"4.4.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      The present study aims to evaluate the clinical efficacy and safety of\n                      <jats:italic toggle=\"yes\">Tripterygium wilfordii<\/jats:italic>\n                      Hook (TwH) combined with angiotensin receptor blockers\/ACE inhibitors (ARB\/ACEI) in the treatment of diabetic kidney disease (DKD) stage IV.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched China National Knowledge Internet (CNKI), the Chinese Biomedical Database, Embase and PubMed for articles about TwH combined with ARB\/ACEI in treating DKD stage IV and set the study inclusion and elimination standards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 22 randomized controlled trials (RCTs) with 1414 participants were collected for detailed evaluation. The meta-analysis results suggested that compared with the controls, the combined group showed significant effects in reducing 24-h urinary protein [mean difference (MD) = \u22120.87, 95% confidence interval (CI) = (\u22121.03, \u22120.71)], raising serum albumin [MD = 4.14, 95% CI (3.43, 4.85)] and the total efficiency [odds ratio (OR) = 4.84, 95% CI (3.33, 7.03)], with no statistical difference in serum creatinine between both groups [MD = \u22123.02, 95% CI (\u22126.40, 0.37),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&gt;\u200a.05]. However, the risk of adverse reactions increased by 8% [Risk Difference (RD) = 0.08, 95% CI (0.05, 0.11)] in the combination.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>TwH combined with ARB\/ACEI in the treatment of DKD stage IV is superior to the monotherapy of ARB\/ACEI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000014604","type":"journal-article","created":{"date-parts":[[2019,3,17]],"date-time":"2019-03-17T07:46:07Z","timestamp":1552808767000},"page":"e14604","source":"Crossref","is-referenced-by-count":19,"title":["Clinical efficacy and safety of Tripterygium wilfordii Hook in the treatment of diabetic kidney disease stage IV"],"prefix":"10.1097","volume":"98","author":[{"given":"Daijin","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Nephrology, the Second Affiliated Hospital of Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zuo","sequence":"additional","affiliation":[{"name":"Grade 2016, the First Clinical Medical College of Nanchang University, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, the Second Affiliated Hospital of Nanchang University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00467-014-2888-2","article-title":"Urinary biomarkers for early diabetic nephropathy: beyond albuminuria","volume":"30","author":"Lee","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2013.10.051","article-title":"Frontiers in diabetic kidney disease: introduction","volume":"63","author":"Robert","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2012.10.001","article-title":"Epidemiology of diabetic kidney disease","volume":"97","author":"Reutens","year":"2013","journal-title":"Med Clin North Am"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ki.1997.2","article-title":"Understanding the nature of renal disease progression","volume":"51","author":"Remuzzi","year":"1997","journal-title":"Kidney Int"},{"key":"R6-20230914","first-page":"2015","article-title":"Present and future in the treatment of diabetic kidney disease","author":"Quiroga","year":"2015","journal-title":"J Diabet Res"},{"key":"R7-20230914","first-page":"303","article-title":"Treatment of membranous nephropathy with Tripterygium wilfordii and steroid: a prospective randomized control trial","volume":"18","author":"Liu","year":"2009","journal-title":"Chin J Nephrol Dial Transplant"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.transproceed.2006.03.017","article-title":"Clinical trial of Tripterygium wilfordii Hook F. in human kidney transplantation in China","volume":"38","author":"Ji","year":"2006","journal-title":"Transplant Proc"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3892\/ijmm.2017.3068","article-title":"Multi-glycoside of Tripterygium wilfordii Hook. f. attenuates glomerulosclerosis in a rat model of diabetic nephropathy by exerting anti-microinflammatory effects without affecting hyperglycemia","volume":"40","author":"Wu wei","year":"2017","journal-title":"Int J Mol Med"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3892\/etm.2013.1226","article-title":"Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy","volume":"6","author":"Ma","year":"2013","journal-title":"Exp Ther Med"},{"key":"R11-20230914","first-page":"782","article-title":"Triptolide: a potent inhibitor of NF-\u039aB in T-lymphocytes","volume":"21","author":"Liu","year":"2000","journal-title":"Acta Pharmacol Sin"},{"key":"R12-20230914","first-page":"611","article-title":"Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: a meta-analysis","volume":"11","author":"Hong","year":"2016","journal-title":"De Gruyter Open"},{"key":"R14-20230914","first-page":"112","article-title":"ARB combined with Tripterygium glycosides in the treatment of diabetic nephropathy","volume":"16","author":"Cai","year":"2012","journal-title":"J Clin Med Pract"},{"key":"R15-20230914","first-page":"5312","article-title":"Clinical observation of Tripterygium wilfordii combined with Irbesartan in the treatment of diabetic nephropathy with large amount of proteinuria","volume":"31","author":"Huang","year":"2010","journal-title":"Jilin Med J"},{"key":"R16-20230914","first-page":"84","article-title":"Clinical observation of Valsartan combined with Tripterygium wilfordii in the treatment of proteinuria in type 2 diabetic nephropathy","volume":"5","author":"Wang","year":"2012","journal-title":"Chin J Clin Rational Drug Use"},{"key":"R17-20230914","first-page":"32","article-title":"Clinical observation of Tripterygium wilfordii combined with Irbesartan in the treatment of diabetic nephropathy with large amount of proteinuria","volume":"5","author":"Tan","year":"2010","journal-title":"Natl Med Front China"},{"key":"R18-20230914","first-page":"416","article-title":"Effects of Tripterygium glycosides on urinary monocyte chemotaxis protein-1 in diabetic nephropathy patients","volume":"25","author":"Song","year":"2005","journal-title":"Chin J Integr Traditional West Med"},{"key":"R19-20230914","first-page":"1029","article-title":"Tripterygium glycosides adjuvant treatment of diabetic nephropathy: reported of 53 cases","volume":"38","author":"Li","year":"2014","journal-title":"Heilongjiang Med J"},{"key":"R20-20230914","first-page":"15","article-title":"A clincial study of Tripterygium glycosides adjuvant treatment of diabetic nephropathy","volume":"26","author":"Yun","year":"2014","journal-title":"Nei Mongol J Traditional Chin Med"},{"key":"R22-20230914","first-page":"811","article-title":"Clinical observation on 46 cases of diabetic nephropathy treated with Tripterygium wilfordii and Valsartan","volume":"12","author":"Zhao","year":"2011","journal-title":"Chin J Integr Traditional West Nephrol"},{"key":"R23-20230914","first-page":"1016","article-title":"Clinical observation of Tripterygium wilfordii polyglycoside tablets combined with Benapril in the treatment of diabetic nephropathy with proteinuria","volume":"34","author":"Chen","year":"2013","journal-title":"Shaanxi J Traditional Chin Med"},{"key":"R24-20230914","first-page":"5789","article-title":"Analysis of the effect of Valsartan combined with Tripterygium glycosides in the treatment of diabetic nephropathy: reported 78 cases","volume":"34","author":"Pu","year":"2013","journal-title":"Jilin Med J"},{"key":"R25-20230914","first-page":"90","article-title":"Clinical analysis of tripterygium glycosides combined with benazepril in the treatment of diabetic nephropathy","volume":"12","author":"Xu","year":"2014","journal-title":"J Bethune Military Med Coll"},{"key":"R26-20230914","first-page":"753","article-title":"Clinical observation on the effect of Valsartan combined with Tripterygium glycosides in the treatment of diabetic nephropathy stage IV","volume":"18","author":"Wu","year":"2018","journal-title":"Chin Rem Clin"},{"key":"R27-20230914","first-page":"15","article-title":"Clinical observation of Benapril comined with Tripterygium wilfordii in the treatment of diabetic nephropathy","volume":"12","author":"Bao","year":"2016","journal-title":"J Pract Diabetol"},{"key":"R28-20230914","first-page":"94","article-title":"Clinical efficacy of Tripterygium wilfordii combined with Valsartan in the treatment of diabetic nephropathy with massive proteinuria","volume":"7","author":"Zhou","year":"2013","journal-title":"For all Health"},{"key":"R29-20230914","first-page":"394","article-title":"Clinical observation of Tripterygium wilfordii combined with Valsartan in the treatment of diabetic nephropathy with massive proteinuria","volume":"21","author":"Wu","year":"2012","journal-title":"Modern J Integr Traditional Chin West Med"},{"key":"R30-20230914","first-page":"43","article-title":"Clinical study of Tripterygium glycosides combined with Valsartan in the treatment of diabetic nephropathy","volume":"13","author":"Li","year":"2011","journal-title":"Chin Commun Doctors"},{"key":"R31-20230914","first-page":"156","article-title":"Clinical observation on the effect of Tripterygium glycosides combined with Valsartan tablets in the treatment of diabetic nephropathy","volume":"5","author":"Cao","year":"2011","journal-title":"China Prac Med"},{"key":"R32-20230914","first-page":"95","article-title":"Clinical observation on treating diabetic nephropathy during IV period with the Tripterygium glycosides tablets","volume":"8","author":"Xu","year":"2016","journal-title":"Clin J Chin Med"},{"key":"R33-20230914","first-page":"248","article-title":"A clincial study of tripterygium glycosides tablets adjuvant treatment of diabetic nephropathy during IV period","volume":"24","author":"Zhang","year":"2015","journal-title":"China Pharmaceut"},{"key":"R34-20230914","first-page":"553","article-title":"Losartan combined with tripterygium glycosides in the treatment of diabetic nephropathy during IV period","volume":"25","author":"Yang","year":"2016","journal-title":"Proc Clin Med"},{"key":"R35-20230914","first-page":"182","article-title":"Clinical study of Tripterygium glycosides combined with Irbesartan in the treatment of diabetic nephropathy","volume":"8","author":"Wang","year":"2013","journal-title":"China Prac Med"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R37-20230914","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"Friedrich","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"R38-20230914","first-page":"141","article-title":"Triptolide attenuate oxidative stress, NF-kB activation and multiple cytokine gene expression in murine peritoneal macrophage","volume":"17","author":"Wu","year":"2006","journal-title":"Int J Mol Med"},{"key":"R39-20230914","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jep.2011.04.046","article-title":"Multi-glycoside of Tripterygium wilfordii Hook. f. reduces proteinuria through improving podocyte slit diaphragm dysfunction in anti-Thy1.1 glomerulonephritis","volume":"136","author":"Wan","year":"2011","journal-title":"J Ethnopharmacol"},{"key":"R40-20230914","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000316707","article-title":"Renoprotective effects of various angiotensin II receptor blockers in patients with early-stage diabetic nephropathy","volume":"33","author":"Nakamura","year":"2010","journal-title":"Kidney Blood Press Res"},{"key":"R41-20230914","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"R42-20230914","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/ajh\/hpt085","article-title":"Identification of the stages of diabetic nephropathy at which angiotensin II receptor blockers most effectively suppress albuminuria","volume":"26","author":"Ogawa","year":"2013","journal-title":"Am J Hypertens"},{"key":"R43-20230914","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/0253-7613.153420","article-title":"A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy","volume":"47","author":"Pathak","year":"2015","journal-title":"Indian J Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201903150-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:53:18Z","timestamp":1694713998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201903150-00010"}},"subtitle":["A meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014604","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}